The nonprofit Tri-Institutional Therapeutics Discovery Institute (Tri-I TDI) was established three years ago as a partnership between Takeda Pharmaceuticals Ltd. and three New York-based academic institutions – Memorial Sloan Kettering, The Rockefeller University and Weill Cornell Medical College – to translate potential targets into pharmaceutical candidates.
